ubmslateCN-logo-ubm

CN Mobile Logo

Topics:

Triple-Negative Breast Cancer

Triple-Negative Breast Cancer

The KEYNOTE-012 trial shows that pembrolizumab has activity and acceptable toxicity as single-agent therapy in advanced triple-negative breast cancer.

Two leading breast cancer experts debated the proposition that platinum-based or other additional systemic agents should be used in difficult-to-treat cases of high-risk triple-negative breast cancer.

In this interview we discuss the current challenges to treating triple-negative breast cancer and look at avenues of promising research.

The addition of carboplatin to a neoadjuvant chemotherapy regimen resulted in improvements in disease-free survival for women with triple-negative breast cancer.

According to the results of a genomic analysis, several genetic characteristics linked with aggressive cancer are more common in the breast tumors of African American women compared to their white counterparts.

Adjuvant radiation therapy after lumpectomy improves survival for elderly women with early-stage, triple-negative breast cancer, according to a study to be presented at the 2015 ASCO Breast Cancer Symposium.

In an ongoing study, the immunotherapy MPDL3280A continues to be well-tolerated and to show signs of activity in triple-negative breast cancer patients.

Pages

Subscribe to Triple-Negative Breast Cancer on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.